Ketoprofen versus Indomethacin in the Treatment of Acute Gouty Arthritis.

Abstract

A cross-sectional study of 80 patients was intended to evaluate the efficacy of Ketoprofen versus indomethacin in the treatment of acute gouty arthritis. This study was designed by making a comparison between the types of treatment used, in addition to knowing the type of statistical relationship. Demographic information and data were collected from different hospitals in Iraq during a one-year study period from March 2022 to February 2023. This study was conducted for patients with acute gouty arthritis, an extremely painful condition; NSAIDs are the first-line medication for a gouty arthritis attack. In this study, drug efficacy was assessed using joint tests before the start of the study, after five days, and at the end of treatment. On the background of treatment and, by the fifth day of treatment, there was a statistically significant improvement in all clinical indicators used to assess joint syndrome in patients with gout, and this trend increased at the end of the treatment course. Therefore, the attack of arthritis was stopped on the fifth day, and we conclude from this study that there is a statistical relationship between the use of the treatment and the improvement of patient outcomes through the significant increase in the quality of life for patients.